Evidence map›Paper›PMID 35836236›Full record

ArticleJournal of nanobiotechnology2022

A new polysaccharide platform constructs self-adjuvant nanovaccines to enhance immune responses.

Sisi Chen, Liu Yang, Xia Ou, Jin-Yu Li, Cheng-Ting Zi, Hao Wang, Jiang-Miao Hu, Ye Liu

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 22 citations in OpenAlex.

  1. Molecules (Basel, Switzerland) · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Sisi Chen *Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, 650000, Yunnan, China.
Liu Yang *State Key Laboratory of Phytochemistry and Plant Resources in West China, and Yunnan Key Laboratory of Natural Medicinal Chemistry, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, 650201, Yunnan, China.
Xia Ou *School of Medicine, Kunming University of Science and Technology, Kunming, 650201, Yunnan, China.
Jin-Yu Li *State Key Laboratory of Phytochemistry and Plant Resources in West China, and Yunnan Key Laboratory of Natural Medicinal Chemistry, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, 650201, Yunnan, China.
Cheng-Ting ZiCollege of Science, Yunnan Agricultural University, Kunming, 650201, Yunnan, China.
Hao WangCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, CAS Center for Excellence in Nanoscience, Beijing, 100190, China. wanghao@nanoctr.cn.
Jiang-Miao HuState Key Laboratory of Phytochemistry and Plant Resources in West China, and Yunnan Key Laboratory of Natural Medicinal Chemistry, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, 650201, Yunnan, China. hujiangmiao@mail.kib.ac.cn.
Ye LiuInstitute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, 650000, Yunnan, China. liuye@imbcams.com.cn.
Chinese Academy of Sciences · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNKunming University of Science and Technology · CNNational Center for Nanoscience and Technology · CNYunnan Agricultural University · CN

Funding

Kunming Science and Technology Bureau 2020-1-N-038Leading Medical Talents Program of Health Commission of Yunnan Province L-2018013Poverty alleviation through science and technology projects of Chinese Academy of Sciences KFJ-FP-201905technology transfer into Yunnan project 202003AD150005the Basic Research Program of Yunnan Province 202101AS070051the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science 2021-I2M-2-043, 2020-I2M-2-014the National Basic Research Program of China 2020YFA0710700the Non-Profit Central Research Institute Fund of Chinese Academy of Medical Sciences 2018RC310021the Young and Middle Aged Academic and Technical Leaders Program of Yunnan Province 202005AC160010
6 · The paper itself

Abstract

backgroundNanovaccines have shown the promising potential in controlling and eradicating the threat of infectious diseases worldwide. There has been a great need in developing a versatile strategy to conveniently construct diverse types of nanovaccines and induce potent immune responses. To that end, it is critical for obtaining a potent self-adjuvant platform to assemble with different types of antigens into nanovaccines.

resultsIn this study, we identified a new natural polysaccharide from the rhizomes of Bletilla striata (PRBS), and used this polysaccharide as a platform to construct diverse types of nanovaccines with potent self-adjuvant property. In the construction process of SARS-CoV-2 nanovaccine, PRBS molecules and RBD protein antigens were assembled into ~ 300 nm nanoparticles by hydrogen bond. For HIV nanovaccine, hydrophobic effect dominantly drove the co-assembly between PRBS molecules and Env expression plasmid into ~ 350 nm nanospheres. Importantly, PRBS can potently activate the behaviors and functions of multiple immune cells such as macrophages, B cells and dendritic cells. Depending on PRBS-mediated immune activation, these self-adjuvant nanovaccines can elicit significantly stronger antigen-specific antibody and cellular responses in vivo, in comparison with their corresponding traditional vaccine forms. Moreover, we also revealed the construction models of PRBS-based nanovaccines by analyzing multiple assembly parameters such as bond energy, bond length and interaction sites.

conclusionsPRBS, a newly-identified natural polysaccharide which can co-assemble with different types of antigens and activate multiple critical immune cells, has presented a great potential as a versatile platform to develop potent self-adjuvant nanovaccines.

Indexed as

COVID-19NanoparticlesAdjuvants, ImmunologicHumansImmunityPolysaccharidesSARS-CoV-2Adjuvants, ImmunologicPolysaccharidesHIVNanovaccinePolysaccharideSARS-CoV-2Self-adjuvant

Identifiers

PMID35836236
PMCPMC9281129
OpenAlexW4285388653

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.